Roche Reviews Its Research Priorities With Opening Of Translational Research Center
Executive Summary
Oncology may consume a disproportionate percentage of Roche’s R&D budget and generate the bulk of its revenues, but at a day-long symposium celebrating the opening of Roche’s new translational research center in NYC, the company’s scientific leaders highlighted its priorities in other complex diseases.
You may also be interested in...
Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?
Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.
Research And Early Development At Roche, A Work In Progress: An Interview With Mike Burgess
The acting head of Roche pharma research and early development stepped into the job amid major personnel changes in the pharma organization and the consolidation and streamlining of pRED. He spoke with the “The Pink Sheet” about his group’s priorities and the inevitable short-term hit to research productivity.
Roche Shakes Up R&D, Closes Nutley Operations
Roche will shut down its Nutley, N.J., pharma operations – once its U.S. headquarters – by the end of 2013 in a cost-saving measure that will leave only a small group of employees on the East Coast.